

COPY

**RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below), of the subject matter which is claimed and for which a patent is sought on the invention entitled:

EPIDIDYMIS-SPECIFIC RECEPTOR PROTEIN

the specification of which (check applicable box(s)):

☐ is attached hereto
☒ was filed on March 13, 1998 as U.S. Application Serial No. 09/041,745 (Att. Dkt. No. 35-126)
☐ was filed as PCT International application No. _____ on _____
 and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate stated below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) stated below

Application Number	Date/Month/Year Filed
--------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed
------------------------	----------------------

Status: patented

pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof, of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27976; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnham, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334.

1.	Inventor's Signature: <u>C. Esterhoff</u>	Date: <u>17.2.2000</u>
	Inventor: <u>Caroline</u> <u>OSTERHOFF</u> <u>German</u> (first) (last) (citizenship) MI (state/country)	
	Residence: (city) <u>Hamburg</u> (state/country) <u>Germany</u>	
	Post Office Address: <u>Lutterothstr. 91, Hamburg, Germany</u> (Zip Code) <u>20255</u>	
2.	Inventor's Signature: <u>Richard Ivell</u>	Date: <u>17.2.2000</u>
	Inventor: <u>Richard</u> <u>IVELL</u> <u>British</u> (first) (last) (citizenship) MI (state/country)	
	Residence: (city) <u>Hamburg</u> (state/country) <u>Germany</u>	
	Post Office Address: <u>Methfesselstr. 45, Hamburg, Germany</u> (Zip Code) <u>20257</u>	
3.	Inventor's Signature: <u>Christiane Kirchhoff</u>	Date: <u>21.2.2000</u>
	Inventor: <u>Christiane</u> <u>Kirchhoff</u> <u>German</u> (first) (last) (citizenship) MI (state/country)	
	Residence: (city) <u>Bordesholm</u> (state/country) <u>Germany</u>	
	Post Office Address: <u>Caspar von Saldern-Weg 3, Bordesholm, Germany</u> (Zip Code) <u>D 24582</u>	

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

Assistant Commissioner for Patents
Washington, DC 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Osterfoff et al.

Atty. Ref.: 35-188

Serial No. 09/629,437

Group: 1646

Filed July 13, 2000

Examiner: Ulm

For: EPIDIDYMIS-SPECIFIC RECEPTOR PROTEIN

DECLARATION UNDER RULE 132

I, Dr. Ulrich Gottwald, hereby declare as follows:

1. I am employee of Schering AG and presently hold the position of Senior Scientist. A copy of my CV is attached.
2. I have read the above-identified application, including the claims, and the Office Action dated July 18, 2001, issued in connection with the above-identified application.
3. It is my belief that one of ordinary skill in the art would appreciate that the above identified application identifies substantial and specific utilities for the protein of the above-identified application, DNA encoding the protein,

and antibodies which react with and are specific to at least one epitope included in the described protein. I believe one of ordinary skill in the art would appreciate that the above-identified application identifies, for example, at least the following substantial and specific utilities for the disclosed subject matter: methods and treatment of male infertility, such as has been caused by protein metabolism disturbances in the epididymis, and compounds and compositions to perform these methods.

4. To demonstrate the utility of the disclosed subject matter, I have performed, or had performed at my direction, the following experiments.
5. Specifically, the experiments described herein were performed to demonstrate a utility for the disclosed human receptor protein designated HE6 and antibodies against this protein. The human receptor protein HE6 has the amino acid sequence shown in SEQ ID NO:2 of the above-identified application.
6. The following data derived from knockout (i.e., KO) mouse. Specifically a knockout mouse was developed, wherein the murine counterpart of the human HE6 sequence was deleted. The results obtained in the mouse model also show that the human HE6 receptor is useful as a male-specific contraceptive target.

The following outlines the data presented herinafter and attached:

- A. Construction of the knock out
- B. Verification of the knock out
- C. Knock out phenotype
 - C.1. Fertility phenotype/mating experiments
 - C.2. Spermatozoa phenotype

A. Construction of the knock out mouse

A knock out construction was generated using the exon/intron regions upstream of the beginning of the first transmembrane region and downstream of the seven transmembrane domain (7TM) for recombination (see fig.1). After successful recombination the whole 7TM of the murine counterpart of HE6 was deleted. The disrupted 7TM locus was replaced by a beta-galactosidase gene cassette (knock in), allowing the easy monitoring of the expression by means of simple X-Gal staining. LacZ was to be expressed expressed according to the HE6 expression pattern under control of the endogenous HE6 promotor.

Two positive HE6 KO lines (embryonic stem cell line E14) called A78 and A85 have been injected into C57/B16 blastocysts. After reimplantation into pseudopregnant females chimera animals have been obtained. Those with transmitted KO-construct into the germ line have been confirmed by PCR analysis (fig.2). The chimera males were than crossed with wild type

(WT) B16 female mice to produce heterozygous mice. Heterozygous females were mated with WT males to obtain hemizygous KO males with total loss of HE6. The HE6 gene had been mapped previously on the X chromosome in human. Some time later HE6 could be found in public domain databases mapped on position Xp21.3

No apparent lethality of HE6 knock out mice has been found. The relationship between born KO and WT males was as predicted by the Mendel law (fig. 3).

Two independent lines of HE6 KO mice, A78 and A85, have been derived and are used for fertility studies.

B. Verification of the knock out

Using the seven transmembrane region as a probe in the Northern blot no signal was observed in KO mouse (fig. 4).

HE6 protein can be localized by using specific polyclonal antisera derived from the immunization of rabbits with an N-terminal HE6 peptide. HE6 protein is present in WT mice on the kinocilia of epithelial cells of the ductuli efferentes and on the stereocilia of epithelial cells of the initial segment, the caput and partly on the corpus of the epididymis (fig. 9-16). Antibodies against the sequences of the present application therefore were used, as described in the present application, to analyze fertility. In HE6 KO

mice no kinocilia or stereocilia staining was recognizable with the antisera. The preimmune controls were also included.

In addition, the absence of the HE6 protein in KO mice was shown by Western blot analysis (fig. 5)

C. Knock out phenotype

Hemizygous KO males appeared normal and showed no obvious behavioral phenotype. Weight and size of the KO mice were comparable to WT mice. The organ weights of testis, epididymis, seminal vesicle, prostate, kidney, brain, spleen and heart were analyzed. No obvious differences were found when comparing eight KO with eight WT animals of the same litter. Only the weight of the epididymis is significantly reduced in KO male mice (fig. 6).

C.1 Fertility phenotype

The recent data from all the mating experiments is summarized in the attached Table 1. Sixteen KO mice derived from the A78 founder line and six KO mice from the A85 clone have been analyzed in up to three mating experiments.

Results with A78 KO mice: Animals aged up to nine weeks were infertile in 4 out of 13 experiments. In three cases they were dramatically subfertile (litters only one). Nine to twelve week old animals were infertile in

10 out of 15 experiments. Adult mice older than twelve weeks were infertile in 9 out of 13 experiments.

Results with A85 KO mice: similar results as seen with the A78 founder were obtained with the A85 KO mouse. Half of all animals up to 12 weeks were infertile (3/6). In experiments with mice older than 12 weeks 4 out of 6 were infertile.

These results clearly demonstrate that the function of HE6 is essential for male fertility. Even subadult animals have significantly reduced fertility. With increasing age KO mice tend to be infertile.

C.2 Spermatozoa phenotype

Spermatozoa from the cauda epididymis were analyzed. In every case a prominent phenotype was observed. The sperm count was dramatically reduced. About 20% of the normal number of spermatozoa was found (fig.7). The observed motility is estimated at 0 and 1 according to the WHO-categorization.

8. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Dr. Ulrich Gottwald

Date: 31. January 2002